Abstract: Provided are peptoid-peptide macrocycles. The peptoid-peptide macrocycles may have inhibitory activity towards the Wnt signaling pathway. The Wnt signaling pathway is associated with cancer and other diseases and conditions. Such diseases include, for example, pulmonary fibrosis. Also described are methods of making the peptoid-peptide macrocycles, compositions containing the peptoid-peptide macrocycles, and methods of using the peptoid-peptide macrocycles.

Abstract: Modified polypeptides comprising an amino acid sequence having a lysine or derivative thereof functionalized at N6 with a seryl or threonyl group are disclosed, as are bioconjugates comprising the modified polypeptides, and methods for making the bioconjugates.

Abstract: The disclosure provides polypeptide comprising or consisting of an amino acid sequence at least 66%, 70%, 75%, 80%, 82%, 84%, 86%, 88%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% identical to the amino acid sequence selected from the group consisting of SEQ ID NO: 1-91 as shown in Table I, wherein: (a) amino acid residues in upper case are L amino acids, and residues in lower case are D amino acids; (b) X is 2-aminoisobutyric acid (ATB); (c) no amino acid changes at proline or AIB e residues in the reference peptide are permitted; and (d) any amino acid changes must maintain chirality relative to the reference peptide.

Abstract: Provided are peptoid-peptide macrocycles. The peptoid-peptide macrocycles may have inhibitory activity towards the Wnt signaling pathway. The Wnt signaling pathway is associated with cancer and other diseases and conditions. Such diseases include, for example, pulmonary fibrosis. Also described are methods of making the peptoid-peptide macrocycles, compositions containing the peptoid-peptide macrocycles, and methods of using the peptoid-peptide macrocycles.

Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following formula I: wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Abstract: Novel methods to prepare novel polymers are disclosed. Oxazolidinyl compounds according to formula IV: are also disclosed as intermediate compounds that can be reacted with an acid to form a polymer of formula I.

Abstract: Synthetic miniature protein scaffolds are described herein, as are compositions comprising same. Methods for the preparation of the synthetic miniature protein scaffolds and compositions thereof, and their use in preventing and/or treating conditions relating to diseases or disorders related to or associated with protein-protein interactions directly mediated by poly-proline type-II helix and/or beta-strand interactions are also encompassed herein.

Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following formula I: wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.

Abstract: Novel methods to prepare novel polymers are disclosed. Oxazolidinyl compounds according to formula IV: are also disclosed as intermediate compounds that can be reacted with an acid to form a polymer of formula I.

Abstract: Novel hybrid polymers are disclosed that have a structure represented by the following wherein Abiotic oligomer, Polypeptide, X, Y, and R1 are as described herein. The methods to prepare the hybrid polymers via novel oxazolidinyl compounds are also described.